Loading quotes...
Forecast
The analysts' average price target is €4.58 (-18.51%). The median is €1.12 (-80.07%).
| Buy |
3 |
| Hold |
7 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -354.87k | - |
| Net profit | -9.03m | 45.49% |
| EBITDA | -9.18m | 43.49% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €10.81m |
Number of shares | 2.45m |
52-week high/low | €39.63 - €3.63 |
| Dividends | No |
Beta | 0.53 |
P/E ratio | -0.20 |
PEG ratio | -0.01 |
P/B ratio | 0.25 |
P/S ratio | 63.76 |
Company profile
| Name | aTyr Pharma |
| CEO | Sanjay S. Shukla |
| Employees | 58 |
